PPCB (Propanc Biopharma) Total Stockholders Equity: $10.83 Mil (As of Mar. 2026)


PPCB Propanc Biopharma Inc PPCB
29 GF Score
Price $1.62
! 2 Warning Signs
View Full Analysis

What is Propanc Biopharma Total Stockholders Equity?

Propanc Biopharma PPCB -9.04% 29 Total Stockholders Equity is $10.83 Mil as of Mar. 2026. GuruFocus rates PPCB with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Propanc Biopharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $10.83 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Propanc Biopharma's Book Value per Share for the quarter that ended in Mar. 2026 was $11.24. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Propanc Biopharma's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.05.

Propanc Biopharma  (NAS:PPCB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Propanc Biopharma's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(10.828-1)/0.874
=11.24

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Propanc Biopharma's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.544 + 0.03) / 10.828
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma Total Stockholders Equity Related Terms

Propanc Biopharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Propanc Biopharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma Total Stockholders Equity Chart

Propanc Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.07 -3.02 -3.12 -3.78 13.91

Propanc Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.09 13.91 14.36 11.45 10.83
PPCB
29GF Score
Propanc Biopharma Inc PPCB
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $10.83 Mil mean?
Propanc Biopharma (PPCB) has a Total Stockholders Equity of $10.83 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Propanc Biopharma and its competitors.
Is Propanc Biopharma's Total Stockholders Equity too high?
Propanc Biopharma's current Total Stockholders Equity is $10.83 Mil. Overall, Propanc Biopharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Propanc Biopharma's Total Stockholders Equity compare to GRI and BGMS?
Propanc Biopharma's Total Stockholders Equity of $10.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Propanc Biopharma and its competitors. Propanc Biopharma's current Total Stockholders Equity is $10.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Propanc Biopharma stock overvalued right now?
Propanc Biopharma (PPCB) has a current Total Stockholders Equity of $10.83 Mil. The current Total Stockholders Equity is $10.83 Mil. Propanc Biopharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Propanc Biopharma (PPCB), the current Total Stockholders Equity is $10.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Propanc Biopharma Business Description

Address 302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score

Get the complete analysis for PPCB

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.62
Price